Ernexa Therapeutics Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Ernexa Therapeutics Inc. (ERNA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $930.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2021-03-11
- Ernexa Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2020 was $930.00K, a 119.34% increase from fiscal 2019.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2019 was $424.00K, a 523.53% increase from fiscal 2018.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2018 was $68.00K, a 78.48% decline from fiscal 2017.
- Ernexa Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2017 was $316.00K, a 67.15% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $930.00K 10-K · filed 2021-03-11 | |
| 2019-12-31 | $424.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $68.00K 10-K · filed 2020-03-19 | |
| 2017-12-31 | $316.00K 10-K · filed 2019-03-22 | |
| 2016-12-31 | $962.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | $2.44M 10-K · filed 2017-03-09 | |
| 2014-12-31 | $1.68M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $342.00K 10-K · filed 2015-03-27 | |
| 2012-12-31 | $367.00K 10-K · filed 2014-03-31 | -$367.00K 10-K · filed 2013-03-29 |
| 2011-12-31 | -$1.11M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |